Introduction
============

Lyme neuroborreliosis is a tickborne infection caused by the spirochetes of the *Borrelia burgdorferi* sensu lato complex (including *B garinii* and *B afzelii* in Europe). In Europe, Lyme neuroborreliosis is among the most frequent bacterial infections of the nervous system and mainly manifests as a self limiting, subacute, painful meningoradiculitis with concomitant lymphocytic cerebrospinal fluid inflammation.[@ref1] [@ref2] [@ref3] [@ref4] [@ref5] [@ref6] In children, Lyme neuroborreliosis primarily leads to subacute lymphocytic meningitis.[@ref7]

Antibiotic treatment improves neurological symptoms. However, studies on the long term outcome of Lyme neuroborreliosis are scarce and hampered by small study populations, short term follow-up, and lack of adequate comparison cohorts.[@ref3] [@ref8] [@ref9] [@ref10] [@ref11] [@ref12] [@ref13] A systematic review of 44 clinical trials reported a 28% prevalence of residual symptoms after Lyme neuroborreliosis, including fatigue, pain, and neurological or cognitive sequelae. Few of the studies included control cohorts.[@ref14] Improved information on long term prognosis after an episode of Lyme neuroborreliosis is needed by patients, medical staff, and healthcare providers.

We used a nationwide population based matched cohort design to compare long term survival, health, social functioning, and education among patients with Lyme neuroborreliosis and a comparison cohort from the general population. To establish whether potential differences stemmed from family related factors, we also compared the same outcomes among family members of the patient and comparison cohorts.

Methods
=======

Setting
-------

Denmark's population on 31 December 2017 was 5.7 million people. Tax supported healthcare is provided free of charge to all Danish residents. Almost 5000 intrathecal antibody tests for *B burgdorferi* are performed yearly in Denmark.[@ref2]

Data sources
------------

We used a population based nationwide cohort design, as described previously.[@ref15] We used the unique 10 digit personal identification number assigned to all Danish residents at birth or on immigration to track individuals in Danish national health and administrative registries. Data on *B burgdorferi* intrathecal antibody tests came from data files obtained from all Danish microbiology laboratories that performed this test during the period 1 January 1985 to 1 March 2016. *B burgdorferi* specific intrathecal antibody production was measured by capture enzyme linked immunosorbent assays (see supplementary appendix).[@ref16] Additional data came from the Danish Civil Registration System, the Danish National Patient Registry (DNPR), the Danish Cancer Registry, the Employment Classification Module, the Personal Income Statistics database, and the Danish Educational Attainment Registry (see supplementary appendix).

Study population
----------------

### Lyme neuroborreliosis patient cohort

We identified the Lyme neuroborreliosis patient cohort through collaboration with all microbiology laboratories in Denmark. Using electronic and paper laboratory files, we identified all people who had a *B burgdorferi* intrathecal antibody test performed during the period 1 January 1985 to 1 March 2016. From this population, we extracted all patients with a positive *B burgdorferi* intrathecal IgG and/or IgM test who were Danish residents at study inclusion (supplementary figure A). We defined the first date of a positive *B burgdorferi* intrathecal antibody test as the date of study inclusion. We excluded patients from the study if they were not registered with a diagnosis of borreliosis in the DNPR within one year after study inclusion or had a contact with a department of neurology earlier than one year before study inclusion.

### Population comparison cohort

For each Lyme neuroborreliosis patient, we used the Danish Civil Registration System and the DNPR to identify all Danish residents with the same sex and date of birth as the patient who had not tested positive for *B burgdorferi* intrathecal antibodies and who met the study's inclusion and exclusion criteria (other than a diagnosis of borreliosis) described above for the patient cohort. From this population, we extracted 10 people at random for each patient. People in the population comparison cohort were assigned the same date of study inclusion as the Lyme neuroborreliosis patients to whom they were matched.

### Family member cohorts

A diagnosis of Lyme neuroborreliosis may be related to healthcare seeking behaviour and outdoor recreational activities and thereby to higher socioeconomic status. To assess the magnitude of this effect, we used the Danish Civil Registration System to identify siblings and parents of the Lyme neuroborreliosis patients and of members of the population comparison cohort. Family members were assigned the same date of study inclusion as their relatives in the Lyme neuroborreliosis patient cohort or population comparison cohort (supplementary figure A). As registration of parents is complete only for people born after 1957, family members could not be identified for all study participants.

Statistical analysis
--------------------

We ascertained time to death, diagnoses of cancers, and potential medical sequelae (supplementary appendix). We calculated time from date of study inclusion to 1 March 2016, death, emigration, loss to follow-up, or event of interest, whichever came first. We calculated mortality rate ratios and incidence rate ratios as measures of relative risk. We included patients registered with a diagnosis of borreliosis in the DNPR up to one year after study inclusion. As this may introduce immortal time bias, we did a sensitivity analyses in which we calculated time from the later of study inclusion and registration in the DNPR.

For each person in the patient and comparison cohorts, we ascertained the number of hospital inpatient days and outpatient hospital visits, employment status, personal income, number of days of sick leave, receipt of a disability pension, marital status, and number of children for each year starting 10 years before the date of study inclusion, birth, immigration, or start-up date of the registry recording the outcome of interest, up until the earliest of the following events: 10 years after study inclusion, 1 March 2016, death, emigration, or loss to follow-up. We calculated differences in each outcome between the patient and comparison cohorts, with 95% confidence intervals. For children, we ascertained the grade received in written mathematics during the last year of primary school. We calculated time from age 17 to high school graduation and used Kaplan-Meier tables to calculate cumulative incidences of high school graduation at age 25. Analyses of income, sick leave, receipt of a disability pension, and number of children were restricted to people aged 20-60 years at study inclusion. Analyses of sick leave included only people registered as employed. To account for potential differences in comorbidity at time of study inclusion, we calculated the fraction of people with a Charlson Comorbidity Index score greater than 0 at study inclusion.[@ref17] [@ref18] We did similar calculations comparing family members of Lyme neuroborreliosis patients with family members of people in the population comparison cohort. We used SPSS Statistics version 24 and STATA version 14 for the analyses.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Results
=======

During the study period, we identified 3200 people with a positive *B burgdorferi* intrathecal test (supplementary figure A). Of these, 1047 (33%) did not have a diagnosis of borreliosis recorded in the DNPR and 86 (3%) were registered as having had contact with a department of neurology more than one year before study inclusion. After these exclusions, 2067 patients and 20 670 members of the population comparison cohort remained in the study. Patients and members of the comparison cohort were well matched with respect to Charlson Comorbidity Index score and risk of cancer before study inclusion ([table 1](#tbl1){ref-type="table"}). We identified 3793 family members of people in the patient cohort and 37 579 family members of people in the population comparison cohort ([table 1](#tbl1){ref-type="table"}).

###### 

Characteristics of patients diagnosed as having Lyme neuroborreliosis (LNB), members of population comparison cohort, and family members of people in these two cohorts, Denmark, 1985-2016. Values are numbers (percentages) unless stated otherwise

  Characteristics                                                                                        LNB patients (n=2067)   Population comparison cohort (n=20 670)   Family members of LNB patients (n=3793)   Family members of population comparison cohort (n=37 579)
  ------------------------------------------------------------------------------------------------------ ----------------------- ----------------------------------------- ----------------------------------------- -----------------------------------------------------------
  Female sex                                                                                             1160 (56)               11 600 (56)                               1881 (50)                                 18 900 (50)
  Median (interquartile range) age at study inclusion, years                                             45 (11-62)              45 (11-62)                                37 (17-47)                                37 (18-47)
  Age \<16 years at study inclusion                                                                      644 (31)                6440 (31)                                 2264 (60)                                 22 458 (60)
  Born in Denmark                                                                                        2012 (97)               19 385 (94)                               3739 (99)                                 36 045 (96)
  Charlson Comorbidity Index score \>0[\*](#t1n1){ref-type="table-fn"} [†](#t1n2){ref-type="table-fn"}   272 (13)                3135 (15)                                 426 (11)                                  4199 (11)
  Cancer, total[†](#t1n2){ref-type="table-fn"}                                                           99 (4.8)                910 (4.4)                                 67 (1.8)                                  818 (2.2)
  Non-melanoma-skin cancer[†](#t1n2){ref-type="table-fn"}                                                37 (1.8)                318 (1.5)                                 4 (0.1)                                   93 (0.2)
  Haematological cancer[†](#t1n2){ref-type="table-fn"}                                                   10 (0.5)                36 (0.2)                                  1 (0.03)                                  36 (0.1)
  Other cancers[†](#t1n2){ref-type="table-fn"}                                                           52 (2.5)                556 (2.7)                                 62 (1.6)                                  689 (1.8)
  Fathers                                                                                                --                      --                                        920 (24)                                  8822 (24)
  Mothers                                                                                                --                      --                                        999 (26)                                  9662 (26)
  Siblings                                                                                               --                      --                                        1874 (49)                                 19 095 (51)
  Median (interquartile range) observation time, years                                                   11.4 (6.1-16.3)         11.4 (6.3-16.2)                           11.6 (6.3-16.5)                           11.6 (6.4-16.5)
  Total observation time, years                                                                          23 551                  233 740                                   44 100                                    432 625
  Died[‡](#t1n3){ref-type="table-fn"}                                                                    247 (12)                2728 (13)                                 215 (5.7)                                 2278 (6.1)
  Emigrated[‡](#t1n3){ref-type="table-fn"}                                                               74 (3.6)                340 (1.6)                                 36 (0.9)                                  601 (1.6)
  Lost to follow-up[‡](#t1n3){ref-type="table-fn"}                                                       0                       11 (0.05)                                 0                                         16 (0.04)

Modified Charlson Comorbidity Index (CCI) score derived from diagnoses recorded in Danish National Patient Registry at study inclusion. CCI assigns a score to a range of comorbidities known to be predictive of mortality. For simplicity, scores are dichotomised (CCI score=0 and CCI score\>0).

Diagnosed before study inclusion.

During follow-up.

A total of 247 (12%) Lyme neuroborreliosis patients and 2728 (13%) people in the population comparison cohort died during the observation period ([table 1](#tbl1){ref-type="table"}). Mortality was not higher among patients in the Lyme neuroborreliosis cohort (mortality rate ratio 0.90, 95% confidence interval 0.79 to 1.03) or their family members (0.93, 0.81 to 1.07) compared with people in the population comparison cohort and their family members ([table 2](#tbl2){ref-type="table"}, [fig 1](#f1){ref-type="fig"}, supplementary figure B). Fifty nine patients were registered as having borreliosis in the DNPR more than one month after study inclusion, which may have introduced immortal time bias. The mortality estimate was not changed when we calculated time starting from study inclusion versus date of registration in the DNPR, whichever was later (mortality rate ratio 0.90, 0.79 to 1.03).

###### 

Mortality rate ratios and incidence rate ratios for specific diagnoses in Lyme neuroborreliosis (LNB) patients and their families, compared with members of matched general population cohort and their families, Denmark 1985-2016.

                                                                                       LNB patients *v* population comparison cohort members   Family members of LNB patients *v* family members of population comparison cohort
  ------------------------------------------------------------------------------------ ------------------------------------------------------- -----------------------------------------------------------------------------------
  Mortality                                                                            0.90 (0.79 to 1.03)                                     0.93 (0.81 to 1.07)
  Cancer                                                                               1.32 (1.15 to 1.52)                                     1.06 (0.92 to 1.22)
  Non-haematological cancer                                                            1.19 (1.00 to 1.14)                                     1.12 (0.94 to 1.32)
  Haematological cancer                                                                3.07 (2.03 to 4.66)                                     0.25 (0.08 to 0.77)
   Lymphoma                                                                            4.10 (2.20 to 7.64)                                     --
   Myelomatosis                                                                        2.62 (0.98 to 7.019)                                    --
   Leukaemia (not chronic lymphatic leukaemia)                                         1.36 (0.41 to 4.54)                                     --
   Chronic lymphatic leukaemia                                                         3.67 (1.54 to 8.72)                                     --
  Non-melanoma skin cancer                                                             1.49 (1.18 to 1.88)                                     1.11 (0.94 to 1.32)
  Multiple sclerosis                                                                   1.24 (0.37 to 4.12)                                     1.14 (0.52 to 2.49)
  Arthritis \<1 year after study inclusion[\*](#t2n1){ref-type="table-fn"}             9.04 (3.67 to 22.24)                                    1.30 (0.80 to 2.10)
  Arthritis ≥1 year after study inclusion                                              1.58 (0.88 to 2.84)                                     --
  Skin diseases                                                                        0.88 (0.41 to 1.91)                                     0.67 (0.37 to 1.21)
  Cerebral infarction \<1 year after study inclusion[\*](#t2n1){ref-type="table-fn"}   4.85 (2.92 to 8.05)                                     0.99 (0.77 to 1.28)
  Cerebral infarction ≥1 year after study inclusion                                    1.18 (0.93 to 1.50)                                     --
  Heart block or cardiac arrest                                                        1.00 (0.54 to 1.87)                                     0.98 (0.53 to 1.83)

Data for family members of LNB patients versus family members of people in population comparison cohort cover whole study period.

![Cumulative survival of 2067 Lyme neuroborreliosis (LNB) patients and 20 670 members of population comparison cohort](oben042889.f1){#f1}

The risk of a new cancer was higher in the Lyme neuroborreliosis cohort than in the population comparison cohort ([table 2](#tbl2){ref-type="table"}). The increased risk stemmed mainly from a threefold higher risk of haematological cancer among Lyme neuroborreliosis patients; 29 patients and 94 comparison cohort members were diagnosed as having haematological cancer ([table 2](#tbl2){ref-type="table"}, [fig 2](#f2){ref-type="fig"}). The Lyme neuroborreliosis population had increased risks of lymphoma, myelomatosis, and chronic lymphatic leukaemia ([table 2](#tbl2){ref-type="table"}). Mortality after a diagnosis of haematological cancer did not differ substantially between the patients and the population comparison cohort (mortality rate ratio 1.05, 0.65 to 1.69) (supplementary figure C). The increased risk of haematological cancer was evident throughout the study period and was also observed in a sensitivity analysis excluding patients who had a contact with a department of haematology before and up to one year after study inclusion (incidence rate ratio 2.84, 95% confidence interval 1.81 to 4.47). In addition, the risk of non-melanoma skin cancers was almost 50% higher in the patient cohort than in the population comparison cohort. Risks of haematological cancers and non-melanoma skin cancers were not increased among family members of Lyme neuroborreliosis patients ([table 2](#tbl2){ref-type="table"}, supplementary figure B).

![Cumulative incidence of haematological cancer among Lyme neuroborreliosis (LNB) patients and members of population comparison cohort](oben042889.f2){#f2}

We observed no increased risk of multiple sclerosis, skin diseases, heart block, or cardiac arrest in the Lyme neuroborreliosis patients ([table 2](#tbl2){ref-type="table"}, supplementary figure C). Risks of arthritis and cerebral infarction were increased among Lyme neuroborreliosis patients only during the first year after study inclusion ([table 2](#tbl2){ref-type="table"}).

Days of hospital admission and use of outpatient services were considerably higher in the patient cohort than in the general population comparison cohort during the year of Lyme neuroborreliosis diagnosis and then attenuated. Use of outpatient services remained slightly increased among Lyme neuroborreliosis patients for several years after diagnosis, particularly for services in haematology and neurology clinics ([table 3](#tbl3){ref-type="table"}, supplementary figure C). We observed no increased use of inpatient or outpatient hospital services in the family member cohort during the study period ([table 3](#tbl3){ref-type="table"}, supplementary figure D).

###### 

Hospital inpatient days, number of outpatient visits, employment status, personal income, sick leave, proportion receiving disability pension, marital status, number of children, elementary school grades in written mathematics, and cumulative incidence of graduation from high school among patients with Lyme neuroborreliosis (LNB), members of population comparison cohort, and family members of these two cohorts, Denmark 1985-2016

  Years from study inclusion                                                                                               LNB patients   Population comparison cohort   Difference (95%CI)       Family members of LNB patients   Family members of population comparison cohort   Difference (95%CI)
  ------------------------------------------------------------------------------------------------------------------------ -------------- ------------------------------ ------------------------ -------------------------------- ------------------------------------------------ -----------------------
  **Hospital admission (mean inpatient days/year)**                                                                                                                                                                                                                                 
  −2                                                                                                                       0.71           0.54                           0.17 (−0.31 to 0.66)     0.61                             0.69                                             −0.09 (−0.23 to 0.06)
  0                                                                                                                        14.21          0.76                           13.45 (12.78 to 14.12)   0.88                             0.80                                             0.07 (−0.12 to 0.27)
  1                                                                                                                        0.98           0.95                           0.03 (−0.22 to 0.29)     0.95                             0.82                                             0.13 (−0.11 to 0.36)
  5                                                                                                                        0.68           0.90                           −0.22 (−0.45 to 0.02)    0.99                             0.81                                             0.17 (−0.23 to 0.57)
  10                                                                                                                       1.31           0.95                           0.36 (−0.17 to 0.89)     0.87                             0.82                                             0.06 (−0.25 to 0.37)
  **Outpatient visits (mean visits/year)**                                                                                                                                                                                                                                          
  −2                                                                                                                       0.80           0.87                           −0.08 (−0.25 to 0.10)    0.81                             0.85                                             −0.04 (−0.12 to 0.05)
  0                                                                                                                        4.61           1.07                           3.54 (3.13 to 3.95)      1.02                             0.98                                             0.04 (−0.08 to 0.15)
  1                                                                                                                        1.72           1.12                           0.60 (0.03 to 0.90)      1.10                             1.03                                             0.07 (−0.05 to 0.19)
  5                                                                                                                        1.72           1.35                           0.37 (−0.10 to 0.83)     1.17                             1.20                                             −0.03 (−0.15 to 0.10)
  10                                                                                                                       1.71           1.64                           0.07 (−0.40 to 0.54)     1.58                             1.51                                             0.07 (−0.13 to 0.27)
  **Proportion employed (%)** [**\***](#t3n1){ref-type="table-fn"}                                                                                                                                                                                                                  
  −2                                                                                                                       90             86                             3.9 (1.7 to 6.1)         91                               88                                               2.7 (1.4 to 4.0)
  0                                                                                                                        86             82                             3.6 (1.1 to 6.2)         86                               83                                               2.9 (1.4 to 4.4)
  1                                                                                                                        81             80                             0.8 (−2.1 to 3.6)        84                               80                                               3.7 (2.1 to 0.3)
  5                                                                                                                        70             69                             1.5 (−2.1 to 5.1)        79                               76                                               3.7 (1.8 to 5.7)
  10                                                                                                                       51             51                             0.3 (−4.8 to 4.3)        65                               63                                               2.3 (−0.3 to 4.9)
  **Mean yearly income (Danish Kroner, thousands)** [**\***](#t3n1){ref-type="table-fn"}                                                                                                                                                                                            
  −2                                                                                                                       262            245                            17 (6 to 28)             277                              261                                              16 (7 to 25)
  0                                                                                                                        250            248                            2 (−10 to 15)            290                              262                                              27 (2 to 53)
  1                                                                                                                        253            252                            1 (−14 to 16)            284                              264                                              20 (7 to 33)
  5                                                                                                                        259            260                            −1 (−20 to 18)           297                              286                                              11 (−2 to 23)
  10                                                                                                                       230            281                            −51 (−120 to 19)         277                              271                                              5 (−9 to 20)
  **Days of sick leave/year** [**†**](#t3n2){ref-type="table-fn"}                                                                                                                                                                                                                   
  −2                                                                                                                       8.3            9.2                            −0.9 (−3.9 to 2.1)       9.9                              10.2                                             −0.3 (−3.0 to 2.3)
  0                                                                                                                        45.5           10.1                           35.5 (29.7 to 41.2)      9.9                              9.5                                              0.4 (−2.2 to 2.9)
  1                                                                                                                        24.5           9.4                            15.1 (9.7 to 20.5)       9.7                              9.3                                              0.4 (−2.3 to 3.0)
  5                                                                                                                        9.3            9.6                            −0.3 (−3.5 to 3.0)       10.2                             9.3                                              0.8 (−2.1 to 3.8)
  10                                                                                                                       3.8            8.2                            −4.4 (−6.6 to −2.2)      6.6                              7.5                                              −0.9 (−4.1 to 2.4)
  **Proportion on disability pension (%)** [**\***](#t3n1){ref-type="table-fn"}                                                                                                                                                                                                     
  −2                                                                                                                       3.6            5.7                            −2.2 (−3.6 to −0.8)      2.5                              3.2                                              −0.7 (−1.4 to −0.1)
  0                                                                                                                        4.8            6.5                            −1.7 (−3.3 to −0.1)      3.0                              3.9                                              −1.0 (−1.7 to −0.2)
  1                                                                                                                        5.9            7.0                            −1.1 (−2.9 to 0.7)       3.2                              4.3                                              −1.0 (−1.8 to −0.2)
  5                                                                                                                        8.3            9.2                            −0.9 (−3.2 to 1.3)       4.3                              5.7                                              −1.4 (−2.4 to −0.3)
  10                                                                                                                       9.9            8.6                            1.2 (−1.7 to 4.2)        4.8                              7.0                                              −2.2 (−3.5 to −0.8)
  **Proportion married (%)** [**‡**](#t3n3){ref-type="table-fn"}                                                                                                                                                                                                                    
  −2                                                                                                                       72.0           68.9                           3.1 (0.6 to 5.6)         68.3                             65.8                                             2.5 (0.6 to 4.3)
  0                                                                                                                        73.1           70.2                           2.9 (0.4 to 5.3)         70.7                             67.5                                             3.3 (1.5 to 5.1)
  1                                                                                                                        74.0           70.6                           3.4 (0.9 to 5.8)         71.0                             68.2                                             2.7 (0.9 to 4.6)
  5                                                                                                                        77.0           72.2                           4.8 (2.2 to 7.4)         72.6                             69.8                                             2.8 (0.8 to 4.8)
  10                                                                                                                       79.7           73.1                           6.5 (3.5 to 9.5)         73.2                             70.6                                             2.6 (0.3 to 4.9)
  **Proportion divorced (%)** [**‡**](#t3n3){ref-type="table-fn"}                                                                                                                                                                                                                   
  −2                                                                                                                       9.6            10.9                           −1.3 (−2.9 to 0.4)       6.9                              8.4                                              −1.5 (−2.5 to −0.5)
  0                                                                                                                        9.9            11.4                           −1.5 (−3.1 to 0.2)       7.8                              9.6                                              −1.8 (−2.9 to −0.8)
  1                                                                                                                        10.1           11.6                           −1.6 (−3.3 to 0.1)       8.6                              10.1                                             −1.5 (−2.6 to −0.3)
  5                                                                                                                        9.8            12.0                           −2.2 (−4.1 to −0.4)      9.9                              12.3                                             −2.4 (−3.7 to −1.1)
  10                                                                                                                       9.8            13.1                           −3.3 (−5.6 to −1.1)      13.1                             14.9                                             −1.8 (−3.5 to 0.0)
  **Number of children** [**\***](#t3n1){ref-type="table-fn"}                                                                                                                                                                                                                       
  −2                                                                                                                       1.00           1.00                           −0.01 (−0.16 to 0.15)    1.81                             1.71                                             0.10 (0.03 to 0.18)
  0                                                                                                                        1.11           1.16                           −0.05 (−0.20 to 0.10)    1.95                             1.84                                             0.11 (0.03 to 0.19)
  1                                                                                                                        1.17           1.24                           −0.07 (−0.22 to 0.08)    2.01                             1.91                                             0.10 (0.02 to 0.18)
  5                                                                                                                        1.41           1.50                           −0.10 (−0.27 to 0.08)    2.18                             2.14                                             0.03 (−0.05 to 0.12)
  10                                                                                                                       1.72           1.72                           0.00 (−0.19 to 0.19)     2.30                             2.29                                             0.01 (−0.09 to 0.11)
  **Education**                                                                                                                                                                                                                                                                     
  High grade (\>8) in written mathematics in elementary school after diagnosis of LNB (%)[§](#t3n4){ref-type="table-fn"}   52             45                             6 (1 to 12)              43                               42                                               2 (−3 to 6)
  Cumulative incidence of high school completion before age 25 years (%)[¶](#t3n5){ref-type="table-fn"}                    45             38                             7 (1 to 12)              42                               37                                               5 (1 to 10)

Includes only people aged 20-60 years at study inclusion.

Includes only people aged 20-60 years at study inclusion and registered as employed.

Includes only people aged \>20 years at study inclusion.

Includes only siblings of LNB patients and population comparison cohorts.

Includes only people aged \<17 years at study inclusion.

The employment rate for people in the Lyme neuroborreliosis cohort was higher than in the population comparison cohort, although the rate in the patient cohort decreased slightly after study inclusion ([table 3](#tbl3){ref-type="table"}, supplementary figure E). Before study inclusion, the rate of receipt of disability pensions was lower among Lyme neuroborreliosis patients than among members of the population comparison cohort ([table 3](#tbl3){ref-type="table"}). Although the rate of receipt of disability pensions among patients increased after the date of study inclusion, it did not exceed the rate in the population comparison cohort ([table 3](#tbl3){ref-type="table"}, [fig 3](#f3){ref-type="fig"} (top)). We also observed a higher employment rate and a lower rate of receipt of disability pension among family members of Lyme neuroborreliosis patients, compared with family members of people in the general population comparison cohort ([table 3](#tbl3){ref-type="table"}, [fig 3](#f3){ref-type="fig"} (bottom), supplementary figure E).

![Proportion of people aged 20-60 years at study inclusion registered as receiving disability pension. Top: Lyme neuroborreliosis (LNB) patients and members of population comparison cohort. Bottom: family members of LNB patients and family members of population comparison cohort](oben042889.f3){#f3}

Before study inclusion, income was higher among Lyme neuroborreliosis patients than among members of the general population cohort, but it decreased thereafter ([table 3](#tbl3){ref-type="table"}, supplementary figure E). In contrast, the income of family members of Lyme neuroborreliosis patients was higher than that of family members of people in the comparison cohort throughout the observation period ([table 3](#tbl3){ref-type="table"}, supplementary figure E). Among Lyme neuroborreliosis patients, the number of days of sick leave was substantially higher than for members of the comparison cohort during the year of diagnosis. However, two years after diagnosis, the number of days of sick leave did not differ substantially from that for members of the comparison cohort ([table 3](#tbl3){ref-type="table"}, supplementary figure E).

Compared with the population comparison cohort, the marriage rate was increased and the divorce rate decreased among Lyme neuroborreliosis patients, before as well as after study inclusion. We observed a similar trend among family members of patients ([table 3](#tbl3){ref-type="table"}, supplementary figure F). The number of children was almost identical for Lyme neuroborreliosis patients and members of the population comparison cohort, as well as for the two cohorts of family members ([table 3](#tbl3){ref-type="table"}, supplementary figure F). Children diagnosed as having Lyme neuroborreliosis had higher marks in written mathematics in elementary school, and more Lyme neuroborreliosis patients completed high school, compared with members of the comparison cohort ([table 3](#tbl3){ref-type="table"}, [fig 4](#f4){ref-type="fig"}).

![Cumulative incidence of people aged \<17 years at study inclusion graduating from high school. Top: Lyme neuroborreliosis (LNB) patients and members of population comparison cohort. Bottom: family members of LNB patients and family members of population comparison cohort](oben042889.f4){#f4}

Discussion
==========

We did a population based nationwide cohort study of patients with Lyme neuroborreliosis among whom the diagnosis was established by a positive *B burgdorferi* intrathecal antibody test and a clinical diagnosis of Lyme borreliosis. Compared with members of a general population cohort, mortality was not increased among Lyme neuroborreliosis patients. However, Lyme neuroborreliosis patients had an increased risk of haematological and non-melanoma skin cancers. Before their diagnosis, Lyme neuroborreliosis patients, as well as their family members, had higher incomes and employment rates and were less likely to receive disability pensions than people in the comparison cohort and their family members. However, after diagnosis of Lyme neuroborreliosis, income and employment rates decreased and risk of receipt of disability pensions increased slightly in the patient population but not in their family members, relative to people in the comparison cohorts.

Strengths and limitations of study
----------------------------------

Important design features of this study are its large size, population based nationwide design, and complete long term follow-up of the study cohorts. Access to national registries allowed identification of a well matched population based comparison cohort and cohorts of family members. These registries provided complete data on date of death, comorbidity, cancer diagnoses, educational status, income, and disability pension status.

We included only patients with a first time proven positive *B burgdorferi* intrathecal antibody test, which has a high diagnostic specificity for Lyme neuroborreliosis.[@ref16] Furthermore, the number of patients identified was in the same range as annual surveillance reports of Lyme neuroborreliosis.[@ref2] The registry based design precluded access to data on cerebrospinal fluid leucocyte counts and stage of Lyme neuroborreliosis, character of initial neurological symptoms, and antibiotic therapy. Therefore, we were unable to analyse the effect of clinical risk factors on long term prognosis. However, on the basis of the incidence reported in a previous Danish study, it is reasonable to assume that only a minority of patients had late disseminated (chronic or stage III) Lyme neuroborreliosis and that antibiotics were administered according to European treatment guidelines for this condition throughout the study period.[@ref3] [@ref19] By including only patients with a positive *B burgdorferi* intrathecal test, we are likely to have missed some patients with early Lyme neuroborreliosis.

Long term prognosis of patients with post-treatment Lyme disease syndrome has been intensively debated.[@ref5] [@ref6] [@ref12] [@ref20] We must emphasise that our study focuses on patients with Lyme neuroborreliosis and was not designed to evaluate the prevalence of post-treatment Lyme disease syndrome.

Comparison with other studies
-----------------------------

A key finding was the increased risk of haematological cancers up to 10 years after the Lyme neuroborreliosis diagnosis. A previous Danish-Swedish case-control study reported a threefold increased risk of mantle cell lymphoma in patients with a self reported history of Lyme borreliosis or presence of anti-*B burgdorferi* antibodies.[@ref21] In contrast, a large registry based Swedish study observed no increased risk of haematological malignancies among patients with serological evidence of borreliosis.[@ref22] We found that mortality after a diagnosis of haematological cancer did not differ substantially between Lyme neuroborreliosis patients and people in the population comparison cohort; that the increased risk of haematological cancers persisted even after exclusion of patients who were treated at a hospital department of haematology up to one year after study inclusion; and that Lyme neuroborreliosis patients had increased use of haematological outpatient facilities. This indicates that the increased risk of haematological cancers is unlikely to be explained by the presence of clinically manifest haematological diseases before Lyme neuroborreliosis or by misclassification of the haematological disease. Our data do not allow firm conclusions concerning a causal link between risk of haematological cancers and Lyme neuroborreliosis. Patients had a slightly increased risk of being diagnosed as having haematological cancers before their Lyme neuroborreliosis diagnosis ([table 1](#tbl1){ref-type="table"}). Therefore, we may hypothesise that some Lyme neuroborreliosis patients harbour an unrecognised haematological malignancy or premalignant condition making them prone to second stage manifestations of Lyme borreliosis. In line with this hypothesis, invasive pneumococcal infection is associated with increased risk of a later diagnosis of myelomatosis.[@ref23] In addition, monoclonal B cell lymphocytosis increases the risk of infection and subsequent diagnosis of chronic lymphatic leukaemia.[@ref24] It remains possible that patients with an as yet unrecognised haematological cancer may have a higher risk of lumbar puncture and an intrathecal test for *B burgdorferi* antibodies leading to a higher rate of Lyme neuroborreliosis diagnosis in this patient group.

Outdoor activities increase exposure to both ticks and to ultraviolet light. This probably explains the finding of a 50% increased risk of non-melanoma skin cancers in Lyme neuroborreliosis patients.[@ref25]

The increased risk of cerebral infarction during the first year after a Lyme neuroborreliosis episode is probably related to an increased frequency of neuroimaging procedures leading to detection of otherwise non-symptomatic cerebral infarctions. It is also consistent with reports of meningovascular involvement leading to lacunar infarctions secondary to obliteration of small penetrating arteries, primarily in patients with chronic Lyme neuroborreliosis.[@ref26]

Lyme neuroborreliosis has been proposed to increase the risk of subsequent multiple sclerosis.[@ref27] However, we found no increased risk of this disease, consistent with a report on the geographical distribution of borreliosis and death due to multiple sclerosis in the United States.[@ref28]

Increased morbidity is assumed to lead to increased use of hospital services. We observed a slightly increased use of outpatient hospital services in Lyme neuroborreliosis patients even several years after their diagnosis, without a corresponding increased use of these services by their family members. This seemed to be partly due to residual symptoms of Lyme neuroborreliosis, as patients showed excess use of outpatient facilities treating neurological conditions. A US study based on insurance claims data reported that a diagnosis of Lyme borreliosis was associated with higher total healthcare costs and 87% more outpatient visits over a 12 month period compared with controls.[@ref29]

Lyme neuroborreliosis patients diagnosed in childhood and their siblings had higher educational achievement than members of the comparison cohort, indicating that Lyme neuroborreliosis in childhood does not affect cognition or learning ability and that the favourable educational outcome most likely stems from family related factors.

Before the Lyme neuroborreliosis episode, patients and their family members had higher socioeconomic status compared with matched members of the general population cohort. However, after the Lyme neuroborreliosis diagnosis the employment rate and income among patients decreased to levels observed in the comparison cohort. At the same time, family members of Lyme neuroborreliosis patients maintained a higher level of income and employment than did family members of the comparison cohort. This indicates that Lyme neuroborreliosis decreases working capacity in a small fraction of patients, consistent with a Swedish study reporting a 12% rate of disabling sequelae five years after treatment for Lyme neuroborreliosis and with a Danish study that found a 5% rate of disability after a median 33 months of follow-up.[@ref3] [@ref9] Although living with a disabling chronic disease may increase the risk of divorce, we observed an increased marriage rate after the diagnosis of Lyme neuroborreliosis, compared with the general population cohort.[@ref30] [@ref31]

Conclusion
----------

We conclude that a proven diagnosis of Lyme neuroborreliosis does not have a substantial effect on long term survival, health, social functioning, or education. However, a diagnosis of Lyme neuroborreliosis is associated with increased risk of haematological and non-melanoma skin cancers and marginally decreased labour marked attachment.

### What is already known on this topic

1.  In Europe, Lyme neuroborreliosis is among the most frequent bacterial infections of the nervous system, but the long term prognosis of the disease is poorly described

### What this study adds

1.  Lyme neuroborreliosis had no substantial effect on survival, health, and social parameters

2.  Compared with members of the comparison cohort, patients had a threefold higher risk of haematological cancer, almost 50% higher risk of non-melanoma skin cancer, and a slightly higher risk of disability pension

3.  Lyme neuroborreliosis patients have increased risk of haematological and non-melanoma skin cancers but can otherwise be assured that their long term prognosis is excellent
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